S. Venneti

Single-molecule systems for detection and monitoring of plasma circulating nucleosomes and oncoproteins in Diffuse Midline Glioma

This paper develops a single-molecule system to detect and monitor plasma nucleosomes and oncoproteins in Diffuse Midline Glioma patients, showing clinical utility for non-invasive diagnostics.

H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Diffuse Hemispheric Gliomas

This study shows that H3.3-G34R mutations reprogram the tumor immune microenvironment in diffuse hemispheric gliomas, enhancing the efficacy of immune stimulatory gene therapy and leading to long-term survival in treated mice.

Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways

The paper identifies shared molecular features between H3K27M diffuse midline gliomas and PFA ependymomas, linking them to hindbrain developmental pathways.

β-catenin programs a tissue-specific epigenetic vulnerability in aggressive adrenocortical carcinoma

This study shows that β-catenin maintains adrenocortical carcinoma differentiation through chromatin and histone interactions, and that targeting EZH2 can disrupt this process and inhibit tumor growth.

Therapeutic targeting of differentiation state-dependent metabolic vulnerabilities in DIPG

This study identifies metabolic vulnerabilities in DIPG subtypes and shows that targeting these vulnerabilities with specific drugs can extend survival in preclinical models.

Therapeutic reversal of prenatal pontine ID1 signaling in DIPG

This study identifies ID1 upregulation in DIPG tumor cells and shows that CBD can reduce ID1-driven invasiveness in vitro and in vivo.

PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism

This study identifies EZHIP as a PRC2 inhibitor in PFA ependymomas that mimics the H3 K27M oncohistone by disrupting PRC2 activity and H3K27me3 levels.